Avasimibe, an inhibitor of ACAT1, can attenuate BLCA tumorigenesis and induce G1-phase cell-cycle arrest by activating the PPARγ signaling pathway. The gene discussed is PPARG; the disease is bladder transitional cell carcinoma.